Catalyst Pharmaceutical Partners Reports First Quarter 2007 Financial Results

CORAL GABLES, Fla., May 14 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. today reported financial results for the quarter ended March 31, 2007.

First Quarter 2007 Results

For the quarter ended March 31, 2007, the Company reported a net loss of $1,252,078, or $0.10 loss per basic and diluted share, compared to a net loss of $312,829, or $0.05 loss per basic and diluted share for the same period in 2006. First quarter 2007 results were impacted by non-cash charges relating to stock-based compensation in the amount of $200,368, compared to $120,563 in the same period in 2006.

Research and development expenses for the first quarter of 2007 were $762,520, an increase of 368.9% compared to $162,615 in the first quarter of 2006. These include non-cash stock-based compensation of $78,393 and $82,068, respectively. The substantial increase in research and development expenses in the first quarter of 2007 is primarily the result of costs incurred relating to the Company’s development and production of CPP-109 clinical trial material, expenses related to the two upcoming U.S. Phase II clinical trials, expenses relating to the Company’s recently reported bioequivalence study and support by the Company during the quarter for a clinical trial in Mexico that is being conducted by a member of the Company’s Scientific Advisory Board.

General and administrative expenses for the first quarter of 2007 totaled $734,626 an increase of 372.8% compared to $155,382 in the first quarter of 2006. These include non-cash stock-based compensation of $121,975 and $38,495, respectively. General and administrative expenses increased significantly in the first quarter of 2007 due to the Company’s recent additions to its management team so that the Company has the executive management to execute its product development efforts, upcoming clinical trials and fulfill the requirements related to the Company now being a publicly-traded company. As a development stage pharmaceutical company, Catalyst has no revenues to- date.

At March 31, 2007, the Company had cash and cash equivalents totaling $19.1 million and no long-term debt. The Company believes that its existing cash and cash equivalents will be sufficient to meet its projected operating requirements through the next 24 months.

Commenting on today’s news, Patrick J. McEnany, Catalyst’s Chief Executive Officer, noted, “We are pleased with our operational progress for the quarter. We continue to move ahead with our clinical development program for CPP-109. In particular, we are on track to commence our U.S. Phase II clinical trial evaluating CPP-109 as a treatment for cocaine addiction at the end of the second quarter of 2007, to be followed in the third quarter by the commencement of our U.S. Phase II clinical trial evaluating CPP-109 as a treatment for methamphetamine addiction. Further, we recently announced positive top-line results from our bioequivalence study of CPP-109 compared to Sabril(R) Tablets.”

Mr. McEnany continued, “During the quarter, we also welcomed two new members to our Scientific Advisory Board -- Dr. Thomas Kosten and Dr. Richard Rawson. Both Dr. Kosten and Dr. Rawson bring to Catalyst invaluable clinical experience in the area of drug addiction. We look forward to their extensive contributions to the Company. We also appointed Steven R. Miller, Ph.D. as Vice President of Pharmaceutical Development and Project Management. All of these appointments serve to significantly strengthen our team and position us solidly for the commencement of Phase II trials and the ultimate commercialization of CPP-109.”

Bioequivalence Study

On May 9, 2007, Catalyst announced that it has received initial top-line results from a bioequivalence study demonstrating that CPP-109 (Catalyst’s Vigabatrin Tablets) is bioavailable and bioequivalent to Sabril(R) Tablets, the version of vigabatrin marketed in Europe by Sanofi Aventis. These data potentially provide a basis for linking CPP-109 to the extensive body of published pre-clinical and clinical literature on Sabril(R).

As previously stated, CPP-109 has been formulated and manufactured to the Company’s specifications and clinical trial materials are available for use in the upcoming U.S. Phase II studies for cocaine and methamphetamine addiction.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents and four patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven’s vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company’s initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted “Fast Track” status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. For more information about the Company, go to www.catalystpharma.com.

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company’s actual results in future periods to differ materially from forecasted results. A number of factors, including that the final results of our bioequivalence study will be consistent with the top-line results received to date and those factors described in the Annual Report on Form 10-K for 2006 and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 that the Company has filed with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect the Company’s ability to obtain these results. Copies of the Company’s filings with the SEC are available from the SEC or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CATALYST PHARMACEUTICAL PARTNERS, INC. (a development stage company) CONDENSED STATEMENTS OF OPERATIONS (unaudited) For the Three Months Ended March 31, 2007 2006 Revenues $ - $ - Operating costs and expenses: Research and development 762,520 162,615 General and administrative 734,626 155,382 Total operating costs and expenses 1,497,146 317,997 Loss from operations (1,497,146) (317,997) Interest income 245,068 5,168 Loss before income taxes (1,252,078) (312,829) Provision for income taxes - - Net loss $(1,252,078) $ (312,829) Loss per share - basic and diluted $(0.10) $(0.05) Weighted average shares outstanding - basic and diluted 12,518,809 6,887,513 CATALYST PHARMACEUTICAL PARTNERS, INC. (a development stage company) CONDENSED BALANCE SHEETS March 31, 2007 Dec. 31, 2006 (unaudited) ASSETS Current Assets: Cash and cash equivalents $19,064,940 $20,434,702 Interest receivable 86,230 85,787 Prepaid expenses 184,805 67,333 Total current assets 19,335,975 20,587,822 Property and equipment, net 22,180 20,157 Other assets 20,388 11,500 Total assets $19,378,543 $20,619,479 LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable $312,465 $448,072 Accrued expenses 211,881 324,774 Total current liabilities 524,346 772,846 Total stockholders’ equity 18,854,197 19,846,633 Total liabilities and stockholders’ equity $19,378,543 $20,619,479

Catalyst Pharmaceutical Partners

CONTACT: Jack Weinstein, Chief Financial Officer, Catalyst PharmaceuticalPartners, Inc., +1-201-934-4201, jweinstein@catalystpharma.com; or MelodyCarey, of Rx Communications, +1-917-322-2571, mcarey@rxir.com, for CatalystPharmaceutical Partners, Inc.

MORE ON THIS TOPIC